A risk assessment tool for identifying pregnant and postpartum women who may benefit from pre-exposure prophylaxis (PrEP)

Pre-exposure Prophylaxis (PrEP)

In 2012, the US Food and Drug Administration (FDA) approved Truvada to be used as PrEP by HIV negative people who are at high risk of sexually acquired HIV infection. The US Centre for Disease Control has since developed guidelines and recommended PrEP be used by people at high risk of HIV acquisition via sexual transmission or injection drug use (http://www.cdc.gov/hiv/prevention/research/prep/).

Perceptions of HIV Pre-exposure prophylaxis (PrEP) among young pregnant women from KwaZulu-Natal, South Africa

1412. Predictors of First-Year Medication Adherence in a National Cohort of Veterans Initiating Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Infection Michael Ohl, MD, MSPH; Kelly Richardson, PhD; Brice Beck, MA; Bruce Alexander, PharmD; Puja Van Epps, MD; Marissa Maier, MD; Brian Lund, PharmD and Mary Vaughan-Sarrazin, PhD; Division of Infectious Diseases, Department of Internal Medicine, Un...

Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach

INTRODUCTION HIV prevention during pregnancy and lactation is critical for both maternal and child health. Pregnancy provides a critical opportunity for clinicians to elicit women's vulnerabilities to HIV and offer HIV testing, treatment and referral and/or comprehensive HIV prevention options for the current pregnancy, the postpartum period and safer conception options for future pregnancies. ...

Perspectives of women prescribed HIV pre-exposure prophylaxis (PrEP)

Identifying patients who may benefit from treatment